Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Phase 1 dosing is expected to finish by the end of 2025
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Upgrades 2025 full-year CDMO sales and margin outlook
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
Subscribe To Our Newsletter & Stay Updated
